Clinical trial NCT05222061: A Study of Drug Coated Balloon For Treating the Side Branch in Complex Bifurcation Lesions
Official title: A ProSpecTivE, RaNdomIzed Trial of Drug Coated Balloon For tReating the Side
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Coronary Artery Disease
Keywords: Drug coated balloon, coronary bifurcation
Lead sponsor: Meshalkin Research Institute of Pathology of Circulation
Sponsor class: NETWORK
First posted: 2022-02-03
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Hypothesis: In patients undergoing coronary stenting for the true bifurcation lesions, main branch stenting followed by side branch dilatation with drug coated balloon is superior to the provisional-stenting strategy in terms of late lumen loss at 12 months.

Detailed description: Although drug-eluting stents are still the default interventional treatment of coronary artery disease, drug-coated balloons (DCBs) represent an alternative therapeutic strategy in certain anatomic conditions. Although their use is established for in-stent restenosis of both bare-metal and drug-eluting stents, recent clinical data demonstrate promising results in de novo small-vessel disease, myocardial infarction and bifurcation settings.

Patients with coronary bifurcation lesions account for approximately 15% to 20% of all coronary lesions in coronary interventional procedures. Despite the use of drug-eluting stents, treating bifurcation lesions remains challenging especially in settings of side branch involvment. PCI of such lesions is associated with lower immediate angiographic and clinical success and higher rates of restenosis, which, in addition, are more challenging to treat compared to non-bifurcated lesions.

The optimal treatment of patients with biffurcations lesions involving SB is as yet undefined. Despite provisional stenting strategy is the preferred technique for most patients. Several studies demonstrated that two-stent techniques may be preferable in patients with true bifurcation lesions. However, as a general approach, the EBC suggests conducting PCI procedures with the aim of limiting the amount of stent metal implanted.

In this settings the use of DCB for bifurcation lesions may have some advantages. DCB provides a smaller profile compared with DES, allowing better SB access. The lack of foreign body implantation with DCB obviates the risk for stent thrombosis and may allow for a shorter duration of dual-antiplatelet therapy compared with DES.

To date, there have been very few clinical trials on the treatment of bifurcation lesions with drug-eluting balloons and all of these included only a small cohort of patients.

Early studies looking into the use of a BMS in the MB in combination with a DCB in the SB demonstrated a low late lumen loss in the SB when treated alone with a DCB \[9\]; recent observational studies focusing largely on a SB DCB combined with an MB DES strategy showed good SB results.

In the register PEPCAD V, 28 patients with lesions involving coronary bifurcation were treated by DCB Sequent Please in the secondary branch and the main vessel, BMS implantation in the main vessel, opening the stent struts toward the SD with only one balloon. At 9 months, the LLL in the MB was 0.38 ± 0.46 and 0.21 ± 0.48 mm in the SB resulting in an MLD of 2.2 ± 0.60 mm in the MB and 1.7 ± 0.44 mm in the SB. Three patients had angiographic restenosis, and in one a TLR was performed. Two patients experienced a late stent thrombosis at 6 and 8 months.

Improvement in the technique of intervention with the use of DES and DCB was observed in the prospective multicenter, non-randomized study DEBSIDE. Data from 50 patients were included,. Predilatation of both branches was performed with conventional balloons, then provisional stenting of MB using DES, kissing dilatation with conventional balloons. Authors proposed to remove guidewire from the MB in order to reduce the friction of the DCB and the loss of the antiproliferative drug from the surface of the balloon when it was delivered to the SB, to inflate the balloon with a pressure of 8-10 atmospheres for 30 seconds. Coronary angiography after 6 months, showed the LLL in the SB was 0.04 ± 0.34 mm, and in the MB, 0.54 ± 0.60 mm. The revascularization rate at 12 months was 6% and 2% in MB and SB, respectively.

A prospective multicenter study by Iannopollo G. analyzed results of the Agent DCB application in the real-world population. Among the 354 patients included in the registry (450 lesions treated with 508 DCBs), DCBs were used for the treatment of bifurcation lesions in 26%. DCB was inflated in the SB with a pressure of 8 atmospheres for 60 seconds after provisional stenting of the MB with the DES. The frequency of MACE after 544 days was 3.7%.

In the case of restenosis, DCB considered today a valuable alternative to DES, with strong evidence for the treatment of both BMS and DES restenosis. With its advantage of avoiding the creation of a dual stent layer in the coronary arteries, their use seems particularly attractive especially in patients with complex bifurcation lesions. In these settings DCB does seem to be a promising strategy, however, large randomised clinical trials are needed to show the safety and efficacy of this technology.

Eligibility criteria: Inclusion Criteria:

* Main branch and side branch diameter both \>2.5 mm, evaluated based on coronary angiography, performed no later than 6 month before baseline visit;
* Patient ≥18 years old;
* Signed informed consent;
* True bifurcation lesion type 1:1:1 or 0:1:1 or 1:0:1 and
* ischemic symptoms, or
* positive non-invasive imaging for ischemia, or
* positive fractional flow reserve

Exclusion Criteria:

1. ST Elevation Miocardial Infarction \<72 hours preceding;
2. Cardiogenic shock;
3. Chronic total occlusion of either main or side branch of the bifurcation;
4. \>2 other coronary lesions planned for treatment;
5. SYNTAX score \>32;
6. Left main stenosis;
7. In-stent restenosis;
8. Renal function insufficiency: Serum creatinine \> 177 mmol/l; or undergoing hemodialysis;
9. Left ventricular ejection fraction ≤ 30%;
10. Patient life expectancy less than 12 months;
11. Patient's inability to fully cooperate with the study protocol

Primary outcomes:
measure: Late lumen loss for both main branch and side branch
timeFrame: 12 months
Secondary outcomes:
measure: Major Adverse Cardiac Events (MACE)
timeFrame: 3,6,12 months
measure: All-cause death
timeFrame: 3,6,12 months
measure: Stent/vessel thrombosis
timeFrame: 3,6,12 months
measure: Angiographic Binary Restenosis
timeFrame: 12 months
measure: Target Lesion Revascularization
timeFrame: 3,6,12 months
measure: Target Vessel Revascularization
timeFrame: 3,6,12 months
measure: Angina status
timeFrame: 3,6,12 months
measure: Angiographic success in main branch and side branch
timeFrame: immediately after the procedure
measure: Fluoroscopic time
timeFrame: immediately after the procedure
Other outcomes:
Locations:
city: Novosibirsk
country: Russian Federation
facility: Meshalkin National Medical Research Center
state: Novosibirskaya Oblast
Study officials:
References: